Invention Grant
- Patent Title: Mutant calreticulin for the diagnosis of myeloid malignancies
-
Application No.: US16438575Application Date: 2019-06-12
-
Publication No.: US11274350B2Publication Date: 2022-03-15
- Inventor: Robert Kralovics , Thorsten Klampfl , Heinz Gisslinger
- Applicant: CEMM—Forschungszentrum für Molekulare Medizin GmbH
- Applicant Address: AT Vienna
- Assignee: CEMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee: CEMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee Address: AT Vienna
- Agency: InHouse Patent Counsel, LLC
- Agent Michele M Wales
- Priority: EP131846321 20130916,EP131869398 20131001
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886 ; G01N33/574 ; A61K39/00 ; C07K14/47 ; C07K16/18 ; C12N15/113
Abstract:
The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
Public/Granted literature
- US20200040399A1 MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES Public/Granted day:2020-02-06
Information query
IPC分类:
